KR20220131292A - Gip/glp1 공동-효능제 화합물 - Google Patents

Gip/glp1 공동-효능제 화합물 Download PDF

Info

Publication number
KR20220131292A
KR20220131292A KR1020227028667A KR20227028667A KR20220131292A KR 20220131292 A KR20220131292 A KR 20220131292A KR 1020227028667 A KR1020227028667 A KR 1020227028667A KR 20227028667 A KR20227028667 A KR 20227028667A KR 20220131292 A KR20220131292 A KR 20220131292A
Authority
KR
South Korea
Prior art keywords
ethoxy
glu
amino
acetyl
xaa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020227028667A
Other languages
English (en)
Korean (ko)
Inventor
조르그 앨시나-페르난데즈
로버트 앤드류 브라운
로버트 채드윅 커민스
모하메드 엘사예드 하메드 엘사예드
안드레아 레니 게이저
시아니인 라이
홍창 추
브라이언 모건 왓슨
Original Assignee
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 일라이 릴리 앤드 캄파니 filed Critical 일라이 릴리 앤드 캄파니
Publication of KR20220131292A publication Critical patent/KR20220131292A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2235—Secretins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/645—Secretins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
KR1020227028667A 2020-01-23 2021-01-21 Gip/glp1 공동-효능제 화합물 Withdrawn KR20220131292A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062964932P 2020-01-23 2020-01-23
US62/964,932 2020-01-23
PCT/US2021/014302 WO2021150673A1 (en) 2020-01-23 2021-01-21 Gip/glp1 co-agonist compounds

Publications (1)

Publication Number Publication Date
KR20220131292A true KR20220131292A (ko) 2022-09-27

Family

ID=74592824

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227028667A Withdrawn KR20220131292A (ko) 2020-01-23 2021-01-21 Gip/glp1 공동-효능제 화합물

Country Status (13)

Country Link
US (1) US20230265151A1 (https=)
EP (1) EP4093757A1 (https=)
JP (1) JP2023511441A (https=)
KR (1) KR20220131292A (https=)
CN (1) CN115298207A (https=)
AR (1) AR121093A1 (https=)
AU (1) AU2021211451B2 (https=)
BR (1) BR112022014397A2 (https=)
CA (1) CA3165430A1 (https=)
IL (1) IL294955A (https=)
MX (1) MX2022009149A (https=)
TW (1) TWI770781B (https=)
WO (1) WO2021150673A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI912614B (zh) * 2017-12-21 2026-01-21 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
WO2022159395A1 (en) 2021-01-20 2022-07-28 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
JP2024508745A (ja) * 2021-02-17 2024-02-28 イーライ リリー アンド カンパニー Ｇｉｐ／ｇｌｐ１デュアルアゴニスト治療方法
IL310377A (en) 2021-08-30 2024-03-01 Mindrank Ai Ltd Novel aryl ether substituted heterocyclic compound as glp1r agonist
MX2024003236A (es) 2021-09-15 2024-06-19 Viking Therapeutics Inc Composiciones y metodos para el tratamiento de trastornos metabolicos y hepaticos.
CN117586373A (zh) * 2022-08-10 2024-02-23 成都奥达生物科技有限公司 一种长效双激动剂化合物
CN116023444B (zh) * 2022-08-12 2023-08-01 重庆宸安生物制药有限公司 一种gip和glp-1双受体激动剂多肽化合物及其应用
WO2024165571A2 (en) 2023-02-06 2024-08-15 E-Therapeutics Plc Inhibitors of expression and/or function
WO2025125576A2 (en) 2023-12-15 2025-06-19 E-Therapeutics Plc Inhibitors of expression and/or function
WO2025133348A1 (en) 2023-12-22 2025-06-26 E-Therapeutics Plc Inhibitors of expression and/or function
EP4686757A1 (en) 2024-07-31 2026-02-04 e-therapeutics PLC Inhibitors of expression and/or function
WO2025196502A1 (en) 2024-03-20 2025-09-25 North Carolina Agricultural & Technical State University Choline kinase inhibitors as a therapeutic treatment for obesity

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR080592A1 (es) * 2010-03-26 2012-04-18 Lilly Co Eli Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso
WO2012167744A1 (en) * 2011-06-10 2012-12-13 Beijing Hanmi Pharmaceutical Co., Ltd. Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof
JP6228187B2 (ja) * 2012-05-03 2017-11-08 ジーランド ファーマ アクティーゼルスカブ Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法
HK1211232A1 (en) * 2012-12-21 2016-05-20 Sanofi Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists
MX2016005556A (es) * 2013-11-06 2016-07-15 Zealand Pharma As Compuestos agonistas duales de gip-glp-1 y procedimientos.
JO3575B1 (ar) 2015-01-09 2020-07-05 Lilly Co Eli مركبات مساعد مشترك من gip وglp-1
TWI783244B (zh) * 2015-06-22 2022-11-11 美商美國禮來大藥廠 升糖素及glp-1共激動劑化合物
TWI767095B (zh) * 2017-12-21 2022-06-11 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
CN112469731B (zh) * 2018-07-23 2024-11-29 伊莱利利公司 Gip/glp1共激动剂化合物

Also Published As

Publication number Publication date
JP2023511441A (ja) 2023-03-17
IL294955A (en) 2022-09-01
US20230265151A1 (en) 2023-08-24
TW202140528A (zh) 2021-11-01
EP4093757A1 (en) 2022-11-30
AU2021211451B2 (en) 2023-11-02
WO2021150673A1 (en) 2021-07-29
AR121093A1 (es) 2022-04-20
TWI770781B (zh) 2022-07-11
BR112022014397A2 (pt) 2022-10-11
MX2022009149A (es) 2022-12-15
AU2021211451A1 (en) 2022-08-18
CA3165430A1 (en) 2021-07-29
CN115298207A (zh) 2022-11-04

Similar Documents

Publication Publication Date Title
KR102351313B1 (ko) Gip/glp1 공효능제 화합물
JP7658877B2 (ja) インクレチン類似体およびその使用
TWI770781B (zh) Gip/glp1共促效劑化合物
JP6985345B2 (ja) グルカゴン及びｇｌｐ−１共アゴニスト化合物
KR102440323B1 (ko) 인크레틴 유사체 및 그의 용도
US9764004B2 (en) Glucagon receptor agonists
KR102824306B1 (ko) 인크레틴 유사체 및 그의 용도
EP4587462A1 (en) Gip and glp-1 dual agonist compounds
JP2026069790A (ja) Ｇｉｐ／ｇｌｐ１共アゴニスト化合物
EA052413B1 (ru) Соединения-коагонисты gip/glp-1
EA048422B1 (ru) Соединения-коагонисты gip/glp1
EA043950B1 (ru) Аналоги инкретина и их применение

Legal Events

Date Code Title Description
A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

D18-X000 Deferred examination requested

St.27 status event code: A-1-2-D10-D18-exm-X000

D19-X000 Deferred examination accepted

St.27 status event code: A-1-2-D10-D19-exm-X000

B11 Application withdrawn

Free format text: ST27 STATUS EVENT CODE: N-1-6-B10-B11-NAP-PC1202 (AS PROVIDED BY THE NATIONAL OFFICE)

D20 Deferred examination resumed

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D20-EXM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

D20-X000 Deferred examination resumed

St.27 status event code: A-1-2-D10-D20-exm-X000

PC1202 Submission of document of withdrawal before decision of registration

St.27 status event code: N-1-6-B10-B11-nap-PC1202